# South Korea Rapid Diagnostics Market > South Korea Rapid Diagnostics Market Research Report By Application (Blood Glucose Testing, Infectious Disease Testing, Cardiometabolic Testing, Pregnancy Fertility Testing, Fecal Occult Blood Testing, Coagulation Testing, Toxicology Testing) and By Product Type (Over the Counter (OTC) Kits, Professional Kits) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 8.8% - **2024:** $ 943.29 Million - **2025:** $ 1,026.3 Million - **2035:** $ 2,385 Million - **Key Players:** Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Danaher Corporation (US), Becton Dickinson and Company (US), Cepheid (US), Hologic Inc. (US), Bio-Rad Laboratories (US) **Report ID:** MRFR/MED/43663-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-korea-rapid-diagnostics-market-45343 --- ## Market Summary ## **South Korea Rapid Diagnostics Market Overview** As per MRFR analysis, the South Korea Rapid Diagnostics Market Size was estimated at 289.0 (USD Million) in 2023.The South Korea Rapid Diagnostics Market Industry is expected to grow from 350.0(USD Million) in 2024 to 850.0 (USD Million) by 2035. The South Korea Rapid Diagnostics Market CAGR (growth rate) is expected to be around 8.401% during the forecast period (2025 - 2035). **Key South Korea Rapid Diagnostics Market Trends Highlighted** The South America Rapid Diagnostics Market is experiencing growth because of some market drivers. This, coupled with a high burden of chronic diseases, is increasing the need for rapid diagnostic tests. Governments in South America are trying to enhance healthcare systems and accessibility to diagnostic tools, which is resulting in the incorporation of rapid tests in routine medical practice. The health ministries in countries like Brazil and Argentina are taking steps to aim the rapid development and distribution of rapid diagnostic tests to enhance early intervention and treatment. This market provides a great scope for further exploitation, specially driven by advancement in technology. Investment opportunity is more favorable due to sustainable growth of diagnostic kits that provide accurate results at point of care and point of care testing. Furthermore, the development of telemedicine and self-testing shifts the focus to accessible rapid diagnostics for patients located in remote, underserved areas. There is also an increasing dependence on molecular diagnostics accompanied by relevant trends of new rapid antigen tests which indicates a movement towards faster, easier and more dependable testing methods. There is also an increasing focus for collaboration between public health agencies and private entities to improve the accessibility and affordability of diagnostic tests. As healthcare needs are met in South America, advancements in the region’s rapid diagnostics will change to address the region’s healthcare challenges and its ecosystem. **South Korea Rapid Diagnostics Market Drivers** **Increasing Demand for Expedited Testing Solutions** The South Korea Rapid Diagnostics Market Industry is witnessing a surge in demand for expedited testing solutions, driven primarily by the need for quick and accurate diagnostics. The COVID-19 pandemic has reshaped the healthcare landscape, emphasizing the need for rapid testing. The Korean Center for Disease Control and Prevention (KCDC) reported over 600,000 COVID-19 cases in 2021, highlighting the urgent requirement for effective diagnostic tools.Furthermore, as healthcare systems strive to enhance patient outcomes, the government has increased funding for rapid testing technology development. This investment aims to offer faster turnaround times, improving diagnosis and treatment processes. The increasing awareness and preference for point-of-care testing (POCT) highlight how essential rapid diagnostics have become within South Korea's healthcare strategy. **Technological Advancements in Diagnostics** Rapid advancements in diagnostic technologies, including the introduction of innovative assays and laboratory-on-a-chip devices, are significantly propelling the South Korea Rapid Diagnostics Market Industry. With the support of local research institutions such as POSTECH and KAIST, developments in microfluidics and biosensing technologies are expected to enhance the accuracy and efficiency of rapid tests. According to advancements provided by various government-funded research grants, notable improvements in sensitivity and specificity of diagnostic tests are anticipated, fostering market growth.The Korean government actively promotes R initiatives that are likely to make cutting-edge rapid diagnostics more widely available to healthcare providers, thereby increasing their adoption across various healthcare settings. **Rising Prevalence of Chronic Diseases** The South Korea Rapid Diagnostics Market Industry is experiencing notable growth due to the increasing prevalence of chronic diseases, including diabetes and cardiovascular conditions. According to the Ministry of Health and Welfare, approximately 4 million people in South Korea were diagnosed with diabetes in 2020, a number that is projected to rise. This growing patient population is driving demand for effective and timely screening methods, particularly rapid diagnostic tests that allow for real-time monitoring of health conditions.As healthcare providers focus on early diagnosis and treatment to manage chronic diseases, the rapid diagnostics segment is likely to see increased application across clinics and hospitals, enabling better patient outcomes. **Government Initiatives for Healthcare Innovations** Government initiatives aimed at fostering healthcare innovations are significantly benefiting the South Korea Rapid Diagnostics Market Industry. The South Korean government has pledged substantial investments in healthcare R as part of their 'K-Healthcare' strategy, which seeks to promote technological advancements in medical diagnostics. This initiative has led to numerous collaborations between public institutions and private companies to develop rapid diagnostic tools.The government’s focus on enhancing the healthcare ecosystem not only facilitates the development of new rapid diagnostic products but also supports regulatory frameworks that expedite their market entry. This pro-innovation stance is expected to catalyze further growth in the rapid diagnostics market, as more cutting-edge solutions become accessible for widespread use. **South Korea Rapid Diagnostics Market Segment Insights** **Rapid Diagnostics Market Application Insights** The Application segment of the South Korea Rapid Diagnostics Market encompasses various critical areas of healthcare, contributing significantly to the overall market growth and transformation. This segment includes Blood Glucose Testing, which plays a vital role in monitoring diabetes management, facilitating timely interventions, and empowering patients with self-management capabilities. Infectious Disease Testing has gained traction, particularly in response to pandemics, as it offers swift diagnostics that can improve patient outcomes and control disease spread, underscoring its importance in both hospitals and point-of-care settings. Cardiometabolic Testing has emerged as a crucial diagnostic avenue, given South Korea's rising prevalence of lifestyle-related diseases, enabling healthcare providers to assess risk factors effectively and create personalized treatment plans.  Pregnancy and Fertility Testing remain significant as they provide essential information for expectant mothers and those trying to conceive, fostering a proactive approach to reproductive health. Fecal Occult Blood Testing is increasingly recognized for its role in early detection, crucial in colorectal cancer prevention strategies, while Coagulation Testing is indispensable for managing blood disorders and guiding therapeutic decisions, thus positioning it as a necessary aspect of acute care settings.Toxicology Testing rounds out the Application segment, playing an essential role in drug testing and forensic investigations, which is vital for public safety and health governance.  The demand within these applications reflects not only the healthcare dynamics in South Korea but also aligns with the government’s push towards enhanced public health initiatives and preventive healthcare measures. As the market continues to evolve, the diverse applications will play a pivotal role in shaping how healthcare services are delivered and accessed across the nation, emphasizing the imperative for timely, accurate diagnostics in improving population health outcomes. With an increasing focus on precision medicine and personalized healthcare, this segment is critical in addressing the unique health challenges faced by the South Korean population today. **Rapid Diagnostics Market Product Type Insights** The Product Type segment of the South Korea Rapid Diagnostics Market showcases significant growth driven by the increasing demand for efficient and timely medical testing solutions. Over the Counter (OTC) Kits have gained prominence as they provide consumers with easy access to testing, allowing for quick decision-making regarding health concerns. This self-testing convenience appeals to a wider demographic, contributing to the growing preference for OTC products. On the other hand, Professional Kits continue to play a vital role in diagnostic accuracy and reliability, catering to healthcare professionals who require precise testing mechanisms for effective patient management.The use of these kits in clinical settings is essential for their contribution to early disease detection, ultimately improving health outcomes. Moreover, the advancements in technology and awareness of preventive healthcare further bolster the importance of these product categories. As consumers become more health-conscious, the demand for both OTC Kits and Professional Kits in the South Korean healthcare landscape is expected to expand, highlighting a dynamic shift towards rapid diagnostic solutions. **South Korea Rapid Diagnostics Market Key Players and Competitive Insights** The South Korea Rapid Diagnostics Market is characterized by a dynamic landscape driven by technological advancements and increasing health awareness among the population. This sector has seen significant growth due to the demand for quick and accurate diagnostic solutions that can cater to various medical needs including infectious disease testing, chronic conditions monitoring, and personalized healthcare advancements. As the healthcare infrastructure continues to evolve, companies in the rapid diagnostics sector are focusing on innovating their product lines to meet regulatory standards and enhance patient outcomes, thereby emphasizing the competitive nature of this market. The competitive insights reveal companies leveraging strategic partnerships, investing in research and development, and expanding their distribution networks to capture larger market shares and improve their service delivery. Fujirebio has established a stronghold in the South Korea Rapid Diagnostics Market by leveraging its expertise in molecular diagnostics and immunoassay technologies. The company’s commitment to innovation is evident in its continuous efforts to develop high-quality diagnostic solutions tailored to local market demands. In South Korea, Fujirebio focuses heavily on biomarkers associated with diseases that are prevalent in the region, ensuring that its product offerings are both relevant and effective. The company benefits from a well-established distribution network and partnerships with local healthcare providers, which enhances its ability to deliver solutions efficiently across hospitals and clinics. The strengths of Fujirebio lie in its research-driven approach, a robust product portfolio, and a reputation for high reliability and accuracy in diagnostics, making it a formidable player in the South Korean market. Abbott, known for its extensive range of healthcare products, plays a significant role in the South Korean Rapid Diagnostics Market. The company offers key products and services that include point-of-care testing solutions and laboratory diagnostic systems, addressing a variety of healthcare needs in the region. Abbott’s strengths include its advanced technology platforms that facilitate rapid testing and diagnostics, providing healthcare professionals with timely information. The company has a solid market presence due to strategic collaborations and mergers that have allowed it to expand its capabilities and product offerings within South Korea. For instance, Abbott’s investment in local research and development initiatives helps tailor their diagnostics solutions to meet national healthcare challenges and regulatory requirements. By continuously introducing innovative products and expanding its reach within the market, Abbott ensures it remains a prominent player within the competitive landscape of rapid diagnostics in South Korea. **Key Companies in the South Korea Rapid Diagnostics Market Include:** - Fujirebio - Abbott - Danaher - bioMérieux - Daiichi Sankyo - Hologic - GenBody - Thermo Fisher Scientific - Ortho Clinical Diagnostics - Roche - Siemens Healthineers - Cepheid - Eiken Chemical - Quidel - BD **South Korea Rapid Diagnostics Market Industry Developments** The South Korea Rapid Diagnostics Market has seen significant developments recently, particularly with firms like Fujirebio, Abbott, and Danaher actively expanding their portfolios. As of October 2023, the market is experiencing growth attributed to advancements in health technology and increased demand for diagnostic solutions amid global health challenges. Companies such as bioMérieux and Hologic have been focusing on enhancing their testing capabilities, reflecting a shift towards advanced rapid diagnostic tools.  In terms of mergers and acquisitions, there have been no major publicly reported transactions involving key players like Roche or Siemens Healthineers. However, industry dynamics have been influenced by partnerships aimed at leveraging technology for more efficient diagnostic processes. The South Korean government is supportive of the rapid diagnostics sector, encouraging innovation to meet public health needs.  Notably, in 2021, Quidel and BD launched collaborative projects in the region, further solidifying the market's competitive landscape. Recent trends also point towards a growing market valuation, positively impacting the accessibility and utilization of rapid diagnostic solutions across healthcare facilities in South Korea. The focus remains on improving diagnostic accuracy and response times in testing, which is critical in the current healthcare landscape. **South Korea Rapid Diagnostics Market Segmentation Insights** - **Rapid Diagnostics Market Application Outlook** - Blood Glucose Testing - Infectious Disease Testing - Cardiometabolic Testing - PregnancyFertility Testing - Fecal Occult Blood Testing - Coagulation Testing - Toxicology Testing - **Rapid Diagnostics Market Product Type Outlook** - Over the Counter (OTC) Kits - Professional Kits ## Market Drivers ### Rising Prevalence of Chronic Diseases The increasing incidence of chronic diseases in South Korea is a pivotal driver for the rapid diagnostics market. As the population ages, conditions such as diabetes, cardiovascular diseases, and respiratory disorders are becoming more prevalent. This trend necessitates timely and accurate diagnostic solutions to manage these health issues effectively. The rapid diagnostics market is responding to this demand by developing innovative testing methods that provide quick results, enabling healthcare providers to make informed decisions. According to recent data, the market for chronic disease diagnostics is projected to grow at a CAGR of approximately 8% over the next five years, highlighting the urgent need for rapid testing solutions in clinical settings. ### Growing Focus on Preventive Healthcare There is a notable shift towards preventive healthcare in South Korea, which is significantly influencing the rapid diagnostics market. This paradigm shift emphasizes early detection and management of diseases, thereby reducing healthcare costs and improving patient outcomes. The rapid diagnostics market is adapting to this trend by offering tests that can be conducted at home or in point-of-care settings, facilitating immediate access to health information. As a result, the demand for rapid testing solutions is expected to rise, with market analysts estimating a growth rate of around 10% annually in the preventive diagnostics segment. This focus on prevention is likely to reshape healthcare delivery in the coming years. ### Technological Innovations in Diagnostic Tools Technological advancements are transforming the landscape of the rapid diagnostics market. Innovations such as microfluidics, biosensors, and artificial intelligence are enhancing the accuracy and speed of diagnostic tests. These technologies enable the development of portable and user-friendly devices that can deliver results in real-time. The rapid diagnostics market is witnessing a surge in the adoption of these advanced tools, which are increasingly being integrated into healthcare systems across South Korea. Market data indicates that the segment for technologically advanced diagnostic tools is expected to grow by 15% over the next few years, driven by the demand for efficient and reliable testing solutions. ### Increased Investment in Healthcare Infrastructure The South Korean government is making substantial investments in healthcare infrastructure, which is positively impacting the rapid diagnostics market. Enhanced funding for healthcare facilities and research initiatives is facilitating the development and distribution of rapid diagnostic tests. This investment is crucial for improving access to healthcare services, particularly in rural areas where traditional diagnostic methods may be less accessible. The rapid diagnostics market is likely to benefit from these developments, as increased funding can lead to the introduction of new products and technologies. Analysts predict that the healthcare infrastructure investment will contribute to a market growth rate of approximately 12% in the coming years. ### Rising Consumer Awareness and Demand for Self-Testing Consumer awareness regarding health and wellness is on the rise in South Korea, driving demand for self-testing solutions in the rapid diagnostics market. Individuals are increasingly seeking convenient and accessible ways to monitor their health, leading to a surge in the popularity of home testing kits. The rapid diagnostics market is responding to this trend by developing a range of self-testing products that cater to various health conditions. This shift towards self-testing is expected to propel market growth, with estimates suggesting a potential increase of 20% in the self-testing segment over the next few years. As consumers prioritize health management, the demand for rapid diagnostics solutions is likely to continue its upward trajectory. ## Future Outlook The [Rapid Diagnostics Market](https://www.marketresearchfuture.com/reports/rapid-diagnostics-market-11687) is projected to grow at an 8.8% CAGR from 2025 to 2035, driven by technological advancements, increasing demand for point-of-care testing, and rising healthcare expenditure. **New opportunities:** - Development of portable diagnostic devices for remote areas - Integration of AI for enhanced diagnostic accuracy - Expansion of telehealth services incorporating rapid testing solutions By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic investments. ## Segment Insights ### By Product: Over-the-Counter Kits (Largest) vs. Professional Kits (Fastest-Growing) In the South Korea rapid diagnostics market, Over-the-Counter (OTC) Kits currently dominate the product segment, holding a significant share among consumers seeking immediate testing solutions. Professional Kits, while smaller in market share, are gaining traction as healthcare facilities increasingly adopt advanced diagnostic tools to enhance patient care and efficiency. Growth trends indicate that the Professional Kits segment is the fastest-growing, driven by technological advancements and an increasing emphasis on point-of-care testing. Factors such as rising health awareness and the demand for quick and reliable diagnostic results are propelling both segments forward. The OTC Kits appeal to a broad audience, while Professional Kits are becoming essential in clinical settings, reflecting changing consumer needs and market dynamics. Over-the-Counter Kits (Dominant) vs. Professional Kits (Emerging) Over-the-Counter (OTC) Kits are considered the dominant segment in the South Korea rapid diagnostics market, primarily favored for their convenience and accessibility. These kits allow consumers to conduct tests at home without professional assistance, catering to the growing demand for quick results. In contrast, Professional Kits are emerging as a crucial player in the market, designed for use in laboratories and healthcare settings. These kits generally feature more sophisticated technology and offer a wider range of tests but require specialized knowledge to operate. The interplay between these two segments illustrates a balance between consumer convenience and clinical efficacy in the rapidly evolving diagnostic landscape. ### By Application: Blood Glucose Testing (Largest) vs. Infectious Disease Testing (Fastest-Growing) In the application segment of the South Korea rapid diagnostics market, Blood Glucose Testing holds the largest market share, driven by the increasing prevalence of diabetes and the growing preference for home healthcare solutions. Infectious Disease Testing follows closely, demonstrating rapid growth due to heightened awareness and demand for early disease detection and management, especially in light of recent global health events. Growth trends in the application segment are characterized by significant advancements in technology and the rise of point-of-care testing. Blood Glucose Testing remains dominant, leveraging innovations that enhance accuracy and ease of use. Conversely, Infectious Disease Testing is experiencing the fastest growth, fueled by increased investments in R&D and the introduction of rapid testing kits, catering to the urgent need for timely diagnosis and treatment in a post-pandemic world. Blood Glucose Testing (Dominant) vs. Infectious Disease Testing (Emerging) Blood Glucose Testing is a dominant player within the application segment of the South Korea rapid diagnostics market, characterized by its established presence and continuous innovation. This segment benefits from a robust consumer base, especially among diabetics who seek convenient, home-testing solutions. Its strong foothold is complemented by a wide range of products that enhance user experience and engagement. In contrast, Infectious Disease Testing is emerging rapidly, driven by increased public health awareness and demand for accessible diagnostic solutions. The rise of telehealth and remote monitoring technologies further propels its growth, making it a critical segment with significant investment potential for future innovations and enhancements. ## Competitive Benchmarking The rapid diagnostics market in South Korea is characterized by a dynamic competitive landscape, driven by technological advancements and increasing demand for timely medical testing. Key players such as Abbott Laboratories (US), Roche Diagnostics (CH), and Siemens Healthineers (DE) are at the forefront, each employing distinct strategies to enhance their market presence. Abbott Laboratories (US) focuses on innovation, particularly in point-of-care testing solutions, which aligns with the growing trend towards decentralized healthcare. Meanwhile, Roche Diagnostics (CH) emphasizes partnerships with local healthcare providers to expand its reach and improve service delivery. Siemens Healthineers (DE) is investing heavily in digital transformation, integrating AI and data analytics into its diagnostic platforms, thereby enhancing operational efficiency and patient outcomes. Collectively, these strategies contribute to a competitive environment that is increasingly centered on technological innovation and strategic collaborations.In terms of business tactics, companies are localizing manufacturing to reduce costs and improve supply chain efficiency. This approach is particularly relevant in a moderately fragmented market where several players vie for market share. The competitive structure is influenced by the collective actions of these key players, who are not only competing on product offerings but also on the reliability and speed of their supply chains. This focus on operational excellence is crucial in a market where rapid response times can significantly impact patient care. In October Abbott Laboratories (US) announced the launch of a new rapid diagnostic test for infectious diseases, which is expected to enhance its portfolio significantly. This strategic move is likely to solidify Abbott's position in the market by addressing the increasing demand for rapid testing solutions, particularly in outpatient settings. The introduction of this test may also facilitate quicker clinical decision-making, thereby improving patient outcomes and operational efficiencies in healthcare facilities. In September Roche Diagnostics (CH) expanded its collaboration with local South Korean biotech firms to co-develop next-generation diagnostic tools. This partnership is strategically important as it allows Roche to leverage local expertise and accelerate the development of innovative solutions tailored to the specific needs of the South Korean market. Such collaborations may enhance Roche's competitive edge by fostering innovation and ensuring that its products are well-suited to local healthcare challenges. In August Siemens Healthineers (DE) unveiled a new AI-driven diagnostic platform aimed at streamlining laboratory workflows. This initiative reflects Siemens' commitment to integrating advanced technologies into its offerings, which could lead to improved diagnostic accuracy and efficiency. The strategic importance of this development lies in its potential to transform laboratory operations, making them more responsive to the demands of modern healthcare. As of November the rapid diagnostics market is witnessing trends such as digitalization, sustainability, and the integration of AI technologies. These trends are reshaping the competitive landscape, with strategic alliances becoming increasingly vital for success. Companies are moving away from price-based competition, focusing instead on innovation, technological advancements, and the reliability of their supply chains. This shift suggests that future competitive differentiation will hinge on the ability to deliver cutting-edge solutions that meet the evolving needs of healthcare providers and patients alike. ## Recent News & Developments The South Korea Rapid Diagnostics Market has seen significant developments recently, particularly with firms like Fujirebio, Abbott, and Danaher actively expanding their portfolios. As of October 2023, the market is experiencing growth attributed to advancements in health technology and increased demand for diagnostic solutions amid global health challenges. Companies such as bioMérieux and Hologic have been focusing on enhancing their testing capabilities, reflecting a shift towards advanced rapid diagnostic tools.  In terms of mergers and acquisitions, there have been no major publicly reported transactions involving key players like Roche or Siemens Healthineers. However, industry dynamics have been influenced by partnerships aimed at leveraging technology for more efficient diagnostic processes. The South Korean government is supportive of the rapid diagnostics sector, encouraging innovation to meet public health needs.  Notably, in 2021, Quidel and BD launched collaborative projects in the region, further solidifying the market's competitive landscape. Recent trends also point towards a growing market valuation, positively impacting the accessibility and utilization of rapid diagnostic solutions across healthcare facilities in South Korea. The focus remains on improving diagnostic accuracy and response times in testing, which is critical in the current healthcare landscape. ## Report Scope | MARKET SIZE 2024 | 943.29(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1026.3(USD Million) | | MARKET SIZE 2035 | 2385.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.8% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Danaher Corporation (US), Becton Dickinson and Company (US), Cepheid (US), Hologic Inc. (US), Bio-Rad Laboratories (US) | | Segments Covered | Product, Application | | Key Market Opportunities | Integration of artificial intelligence in rapid diagnostics enhances accuracy and efficiency in disease detection. | | Key Market Dynamics | Technological advancements drive rapid diagnostics adoption, enhancing healthcare efficiency and patient outcomes in South Korea. | | Countries Covered | South Korea | ## Frequently Asked Questions **Q: What was the market valuation of the rapid diagnostics market in 2024?** A: The market valuation was $943.29 Million in 2024. **Q: What is the projected market valuation for 2035?** A: The projected market valuation for 2035 is $2385.0 Million. **Q: What is the expected CAGR for the rapid diagnostics market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during the forecast period 2025 - 2035 is 8.8%. **Q: Which companies are considered key players in the rapid diagnostics market?** A: Key players include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific. **Q: What are the two main product segments in the rapid diagnostics market?** A: The two main product segments are Over-the-Counter (OTC) Kits and Professional Kits. **Q: What was the market size for Over-the-Counter (OTC) Kits in 2024?** A: The market size for Over-the-Counter (OTC) Kits was $376.0 Million in 2024. **Q: What is the projected market size for Professional Kits by 2035?** A: The projected market size for Professional Kits is $1435.0 Million by 2035. **Q: Which application segment had the highest market size in 2024?** A: In 2024, the Infectious Disease Testing segment had the highest market size at $300.0 Million. **Q: What is the expected market size for Toxicology Testing by 2035?** A: The expected market size for Toxicology Testing by 2035 is $675.0 Million. **Q: How does the market for Blood Glucose Testing compare between 2024 and 2035?** A: The market for Blood Glucose Testing was $56.0 Million in 2024 and is projected to reach $140.0 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-rapid-diagnostics-market-45343*